TYME Announces First Patient Dosed In Phase II OASIS Trial Evaluating The Potential Benefits Of Oral SM-88 For Patients With Metastatic HR+/HER2- Breast Cancer After Treatment With A CDK4/6 Inhibitor
-- Novel oral approach aimed at disrupting cancer metabolism in metastatic HR+/HER2- breast cancer –
-- HR+/HER2- represents 73% of diagnoses and is the largest subtype of breast cancer1 –
--